CLBS:NSD-Caladrius Biosciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.76

Change

+0.05 (+2.92)%

Market Cap

USD 0.10B

Volume

0.98M

Average Target Price

USD 12.00 (+581.82%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.07 (+1.46%)

USD54.66B 20.44 15.09
MRNA Moderna, Inc

+7.04 (+5.26%)

USD53.62B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

-1.19 (-0.25%)

USD51.03B 15.61 12.36
ALXN Alexion Pharmaceuticals, Inc

+0.54 (+0.35%)

USD33.96B 56.79 33.32
BGNE BeiGene, Ltd

-6.35 (-2.02%)

USD29.36B N/A N/A
BNTX BioNTech SE

+7.65 (+6.68%)

USD27.29B -99,999.99 N/A
SGEN Seagen Inc

-1.62 (-1.12%)

USD26.58B 43.50 36.12
RPRX Royalty Pharma plc

+0.37 (+0.88%)

USD25.46B 22.60 15.46
GMAB Genmab A/S

+0.58 (+1.73%)

USD21.63B 26.59 3.09
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CLBS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.08% 72% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.08% 72% C- 70% C-
Trailing 12 Months  
Capital Gain -23.48% 15% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.48% 15% F 5% F
Trailing 5 Years  
Capital Gain -74.86% 22% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.86% 22% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -16.25% 15% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.25% 15% F 7% F
Risk Return Profile  
Volatility (Standard Deviation) 29.44% 88% B+ 56% F
Risk Adjusted Return -55.20% 12% F 6% F
Market Capitalization 0.10B 16% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 93% A 97% A+
Price/Book Ratio 3.19 70% C- 50% F
Price / Cash Flow Ratio -11.73 61% D- 77% C+
EV/EBITDA 0.47 53% F 93% A
Management Effectiveness  
Return on Equity -30.84% 76% C 31% F
Return on Invested Capital -31.04% 69% D+ 24% F
Return on Assets -37.89% 28% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.25 90% A- 84% B
Short Percent 3.09% 74% C 52% F
Beta 1.12 67% D+ 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.